Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT04260893 Terminated - Dry Eye Clinical Trials

Prospective Study To Assess The Safety And Effectiveness Of Tixel Treatment On Dry Eye Symptoms In Asian Patients

DED
Start date: January 23, 2020
Phase: N/A
Study type: Interventional

Pilot study where effect of standard Tixel treatment as used for periorbital wrinkles would be assessed on Dry Eye Disease symptoms and signs in Asian Patients.

NCT ID: NCT04237012 Completed - Dry Eye Syndromes Clinical Trials

ACCURATE Study for Subjects With Dry Eyes

ACCURATE
Start date: December 16, 2019
Phase: Phase 4
Study type: Interventional

To determine treatment and imaging outcomes in bilateral ocular surface disease management with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical over-the-counter artificial tears lubrication management

NCT ID: NCT04235400 Recruiting - Dry Eye Disease Clinical Trials

Multimodal Screening of Dry Eye Disease

MAOS-S
Start date: January 28, 2021
Phase:
Study type: Observational

Two methods allow to evaluate tear breakup time (BUT): without prior dye instillation (No Dye BreakUp Time NDBUT) or after fluorescein instilation (FBUT). The interconnections between those two values are unknown

NCT ID: NCT04217785 Recruiting - Dry Eye Syndromes Clinical Trials

Umbilical Cord Serum Versus Conventional Eyedrops

Start date: January 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Dry eye disease (DED) is a chronic ocular surface disease and the prevalence of DED has been reported as high as 50%. Recently, The international Dry Eyes Workshop II (DEWS II) defines dry eye as a "multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles". A study done by Yoon et al. on 31 patients with severe DED concluded that UCS eye drops are effective and safe in treating severe DED. Studies found that EGF, TGF-β, VEGF and vitamin A levels were significantly higher in UCS than peripheral blood serum(PBS) whereas IGF content was significantly higher in PBS than in CBS. Yoon et al. then conducted another study whereby he compared UCS to AS in treating both Sjögren syndrome and non- Sjögren syndrome patients with severe dry eyes. They concluded that UCS eye drops were more effective in decreasing symptoms and keratoepitheliopathy in severe dry eye syndrome and increasing goblet cell density in Sjögren syndrome compared with AS drops. Despite proven more effective in treating DED, serum eye drops are not yet widely manufactured due to a few reasons. This study is chosen because 1. Not many previous clinical trials done related to UCS eye drops. 2. There were only two clinical trials done before to compare the use of UCS eye drops versus conventional AT eye drops on Hansen's disease and acute ocular chemical burn injury population. 3. To apply the newer technology of Keratograph® 5M in DED assessment. 4. To initiate a proper standard operating procedure for production as well as delivery of serum eye drops which allowing out-patient treatment with serum eye drops possible.

NCT ID: NCT04213248 Recruiting - Dry Eye Clinical Trials

Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD

Start date: February 21, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether Umbilical Mesenchymal Stem Cells (UMSCs) derived Exosomes could alleviate dry eye symptoms in patients with chronic Graft Versus Host Diseases (cGVHD).

NCT ID: NCT04206020 Completed - Dry Eye Syndrome Clinical Trials

Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome

VISTA-2
Start date: December 20, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.

NCT ID: NCT04201574 Completed - Dry Eye Disease Clinical Trials

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Start date: December 16, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease

NCT ID: NCT04184999 Completed - Dry Eye Syndromes Clinical Trials

Effect of Intraoperative Dexamethasone on Post-op Dry Eye

Start date: August 10, 2019
Phase: Phase 4
Study type: Interventional

To compare the signs and symptoms of dry eye after cataract surgery between subjects randomized to receive intraoperative dexamethasone in addition to the use of a standard topical post-op treatment regimen.

NCT ID: NCT04181593 Active, not recruiting - Dry Eye Clinical Trials

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

Start date: November 18, 2019
Phase: Phase 3
Study type: Interventional

This is a phase 3 study to evaluate the safety and efficacy of OmegaD softgels for the treatment of dry eye disease. A daily dose of 2 OmegaD softgels dosed orally BID will be compared to 2 placebo softgels (mineral oil ) dosed orally BID for 84 days. Approximately 300 subjects will be evaluated for their signs and symptoms of dry eye disease and for safety throughout the study.

NCT ID: NCT04172961 Recruiting - Dry Eye Clinical Trials

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

This study will be a randomized, double-blind prospective in 3 clinical sites to compare the efficacy of two currently approved topical ophthalmic drops in the clearing central corneal staining in 90 days prior to elective cataract or LASIK surgery.